B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS

• N. van de Donk,
• M.C. Minnema,
• B. van der Holt,
• F. Schjesvold,
• K.L. Wu,
• A. Capra,
• A. Broyl,
• W.W.H. Roeloffzen,
• A.P.A. Gadisseur,
• G. Pietrantuono,
• L. Pour,
• V. van der Velden,
• T. Lund,
• M. Offidani,
• M. Grasso,
• L. Giaccone,
• M. Cavo,
• T. Silkjaer,
• J. Caers,
• S. Zweegman,
• R. Hajek,
• R. Benjamin,
• A. Vangsted,
• M. Boccadoro,
• F. Gay,
• P. Sonneveld,
• P. Musto

Affiliations

N. van de Donk

1 Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands

M.C. Minnema

2 University Medical Center Utrecht, department of hematology, Utrecht University, Utrecht, the Netherlands

B. van der Holt

3 HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

F. Schjesvold

4 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, NorwayKG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

K.L. Wu

5 Department of hematology, ZNA Stuivenberg, Antwerp, Belgium

A. Capra

6 University of Torino, Torino, Italy

A. Broyl

7 Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands

W.W.H. Roeloffzen

8 Department of Hematology, University Medical Center Groningen, University Groningen, Groningen, the Netherlands

A.P.A. Gadisseur

9 Department of Haematology, Antwerp University Hospital, Edegem, Belgium

G. Pietrantuono

10 Complex Operative Unit Hematology and Stem Cell Transplant IRCCS Oncology Center of Basilicata, Rionero in Vulture, Italy

L. Pour

11 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

V. van der Velden

12 Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

T. Lund

13 Odense Hospital, Odense, Denmark

M. Offidani

14 A.O.U. Ospedali Riuniti di Ancona, Ancona, Italy

M. Grasso

15 Azienda Ospedaliera S Croce e Carle, Cuneo, Italy

L. Giaccone

16 Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

M. Cavo

17 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

T. Silkjaer

18 Aarhus University Hospital, Aarhus, Denmark

J. Caers

19 CHU Liege, Liege, Belgium

S. Zweegman

1 Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands

R. Hajek

20 Department of Hematooncology, University Hospital Ostrava and Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

R. Benjamin

21 King’s College Hospital, London, United Kingdom

A. Vangsted

22 Department of Hematology, Rigshospitalet, Copenhagen, Denmark;

M. Boccadoro

16 Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

F. Gay

16 Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

P. Sonneveld

7 Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands

P. Musto

23 Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, and Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy